July 2022 - BioMedWire (BMW)

FridayJul 29, 2022 11:02 am

Study Suggests Coronavirus Vaccine May Be Linked to Temporary Changes in Menstrual Cycles

A new study has looked into the connection between menstrual health and vaccination against severe coronavirus infections. The researchers were focused on disproving reports that the coronavirus vaccine could affect menstruation cycles of women of reproductive age. These unfounded claims fostered vaccine skepticism among women as well as the general public, despite the lack of sufficient systematic research on the effects of the coronavirus vaccine on menstrual health. For their study, the researchers looked into the correlation between the SARS-CoV-2 infection and COVID vaccination with changes in the menstrual cycle features of more than 3,000 premenopausal healthcare workers. The researchers…

ThursdayJul 28, 2022 11:06 am

Study Finds That Introducing Some Foods to Infants Early Reduces Risks of Allergies

New research has shown that allowing infants to taste foods that contain wheat, milk, eggs and peanuts as early as the age of three months may decrease an infant’s risk of developing a food allergy. The study, which was led by Professor Karin C. Lødrup Carlsen of the Institute of Clinical Medicine at the University of Oslo, discovered that children who were introduced to these allergenic foods weren’t as likely to develop food allergies by the time they were three years old. For a long time now, the Norwegian Directorate of Health has advised that parents postpone introducing food to…

ThursdayJul 28, 2022 10:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearance Enrollment for Phase 1/2a trial has already started Upcoming trial is first time a psilocybin analog will be evaluated for MDD treatment Studies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/QfXhX) to proceed with its planned phase 1/2a first in-human clinical trial and has started enrollment (https://ibn.fm/HxkKp). The study is designed to evaluate Cybin’s proprietary deuterated…

ThursdayJul 28, 2022 9:00 am

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

CDC estimates put the incidence of athlete concussion incidents at 5 to 10 percent of players Currently, there is no FDA-approved medicinal treatment for helping people with concussion injuries Odyssey Health Inc. is a company developing a drug-device combination to treat concussion patients in the first minutes after injury Retired pro soccer and football athletes Abby Wambach, Kurt Warner, and Brett Favre, have formed a Sports Advisory Board for Odyssey Health to help guide and promote public information regarding Odyssey’s treatment developments Wambach recently appeared on the Stock2Me podcast to discuss her interest in concussion research and her role on…

WednesdayJul 27, 2022 11:23 am

Researchers Develop Blood Test to Improve Tumor Diagnosis, Monitoring

Scientists at Massachusetts General Hospital have developed a tool that can detect additional mutations to help improve tumor diagnosis and monitoring. The scientists, who have in the past created a blood test to detect mutations in a glioma-linked gene, published their findings in “Clinical Cancer Research.” Gliomas are a common type of brain tumors that occur in adults. This advancement offers clinicians a strong tool to help uncover the presence of gliomas through the detection of mRNA in a patient’s blood. mRNA are pieces of the genetic material of tumor cells. Prior research was the first to highlight that this…

TuesdayJul 26, 2022 1:46 pm

Research Suggests How Individuals Can Control Unwanted Thoughts

Intrusive or unwanted thoughts are a common human experience. They often appear out of the blue, and in most cases, they tend to be unpleasant and unwanted. Unwanted thoughts and images can cause distress, especially when they force you to think about past traumatic or distressing events. Sometimes these thoughts can be associated with psychiatric disorders, including anxiety, depression and obsessive-compulsive disorder. Nevertheless, intrusive thoughts are a normal part of life despite the distress they can cause, and it is possible for you to control them. According to a study by the Hebrew University of Jerusalem, most people employ a…

TuesdayJul 26, 2022 9:00 am

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

PBS News Hour estimates that, for college students, concussions cost between $446 million and $1.5 billion annually, while for high school students the cost ranges from $5.4 billion to $19.2 billion Odyssey, through its flagship product, PRV-002, hopes to offer the first FDA-approved drug treatment for concussions Once approved, Odyssey is confident that PRV-w002 will bring relief to thousands of victims, reduce the cost of concussion treatment and allow victims to lead normal, healthy, and productive lives The company is currently scheduling a meeting with the FDA to present findings from the phase I trial, as it identifies phase II…

MondayJul 25, 2022 12:49 pm

Study Highlights Concerns on Police Involvement in Emergency Mental Health Transfers

The police don’t have a good reputation when it comes to dealing with individuals with mental health crises. Police encounters have repeatedly proven to be particularly dangerous for people with mental illness, with these encounters often ending in injury and failing to provide the involved individuals the mental help they need. Even so, a recent study has revealed that university health centers in the Ontario region still rely on law enforcement for emergency mental-health transfers. The study, whose findings were reported in the “Canadian Medical Association Journal,” shows that health practitioners often prefer to call the police, even though they…

MondayJul 25, 2022 11:15 am

Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study

Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage Laboratories Recent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug delivery SPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis Company recently announced positive results in subcutaneous delivery of novel liposomes vs. intravenous injection Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company that focuses on fusing traditional therapeutics with psychedelic research, recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage…

MondayJul 25, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine months The pivotal study was designed with four primary objectives Cybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the company’s proprietary CYB004 substance (https://ibn.fm/2Ab0T). Information from the study is expected to help the company accelerate by up to nine months its clinical development pathway of CYB004. “With the closing of this transaction…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: July 2022

Study Suggests Coronavirus Vaccine May Be Linked to Temporary Changes in Menstrual Cycles

Study Finds That Introducing Some Foods to Infants Early Reduces Risks of Allergies

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

Researchers Develop Blood Test to Improve Tumor Diagnosis, Monitoring

Research Suggests How Individuals Can Control Unwanted Thoughts

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

Study Highlights Concerns on Police Involvement in Emergency Mental Health Transfers

Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search